Ex-Genzyme Chief Henri Termeer Signs On As Sarepta Advisor

Sarepta Therapeutics (NASDAQ: [[ticker:SRPT]]) of Cambridge, MA, has hired former Genzyme head Henri Termeer as an advisor as the company waits for word from FDA about its Duchenne muscular dystrophy treatment eteplirsen. As Xconomy reported Monday, Sarepta has asked the agency to start its final review of eteplirsen and decide whether the drug should come to market as a treatment for one version of the rare DMD that affects about 2,000 patients in the U.S. In a statement, Termeer, with decades of experience bringing drugs to market for rare diseases, said he would work with Sarepta on eteplirsen as well as other drugs in its pipeline.

Author: Alex Lash

I've spent nearly all my working life as a journalist. I covered the rise and fall of the dot-com era in the second half of the 1990s, then switched to life sciences in the new millennium. I've written about the strategy, financing and scientific breakthroughs of biotech for The Deal, Elsevier's Start-Up, In Vivo and The Pink Sheet, and Xconomy. View all posts by Alex Lash